AstraZeneca Debate
Full Debate: Read Full DebateDepartment: Department for Science, Innovation & Technology
Paula Barker
Main Page: Paula Barker (Labour - Liverpool Wavertree)Department Debates - View all Paula Barker's debates with the Department for Science, Innovation & Technology
(1 day, 16 hours ago)
Commons ChamberRead Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Urgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Chris Bryant
Of course we feel regretful. We would have preferred to get this over the line but that was not possible, in large measure because AstraZeneca decided that it did not add up in whatever particular way for it. The right hon. Gentleman makes one very good point: we want a manufacturing provision in the country, and my colleague Lord Vallance is working on that very closely with the sector.
Paula Barker (Liverpool Wavertree) (Lab)
Friday’s announcement was deeply disappointing. The Liverpool city region is home to one of Europe’s largest pharma clusters. The Government were prepared to put millions into the project with AstraZeneca, which it has now walked away from. Is that money still on the table for other viable life science projects in our region? Will the Government commit to meet our metro mayor, Steve Rotheram, to discuss that further?
Chris Bryant
That is the cleverest bid for finance that I have ever heard, so my hon. Friend gets an award for that. She is right that we stand ready at any point to assist key investments of this nature, especially in the life sciences sector. The difference between the amount of money that was theoretically made available by the previous Government and the amount that we were prepared to put forward was remarkably small. The issue is how to ensure that similar investments get over the line. Someone from the Department will meet Steve Rotheram.